Baidu
map

Ebiomedicne:中国科学家开发非小细胞肺癌新诊断工具

2015-08-19 佚名 生物谷

由于缺少非小细胞肺癌(NSCLC)的血液检测方法,也没有明显的临床症状,早期阶段的非小细胞肺癌非常难于检测。在一项发表在国际学术期刊Ebiomedicine的最新文章中,来自南京大学的研究人员在血清中发现了5种microRNA,或可作为非小细胞肺癌的诊断标记为该疾病的早期诊断带来曙光。 MiRNA是一类小的单链非编码RNA,在许多疾病中作为关键调控因子发挥作用,并且根据不同miRNA的表

由于缺少非小细胞肺癌(NSCLC)的血液检测方法,也没有明显的临床症状,早期阶段的非小细胞肺癌非常难于检测。在一项发表在国际学术期刊Ebiomedicine的最新文章中,来自南京大学的研究人员在血清中发现了5种microRNA,或可作为非小细胞肺癌的诊断标记为该疾病的早期诊断带来曙光。
 
MiRNA是一类小的单链非编码RNA,在许多疾病中作为关键调控因子发挥作用,并且根据不同miRNA的表达情况还可以诊断多种类型的癌症。在该研究小组之前的研究工作中,他们已经发现人的体液如血清中包含许多稳定的miRNA,因此血清中的miRNA可能在一些癌症的检测中作为生物标记物发挥重大潜能。

在这项最新研究中,研究人员招募了来自中国和美国的438名参与者,其中包括221名NSCLC病人,161名对照和56名良性结节患者。他们利用高通量的Taqman低密度miRNA芯片技术结合qRT-PCR在来自三个不同队列的中国NSCLC病人样本中成功发现了5种血清miRNA在NSCLC病人体内显著增加,随后在一个美国队列中进行了验证,对这5种miRNA能否用作不同种族NSCLC的可靠诊断标记进行了评估。

结果表明这一组合在对NSCLC和对照人群的区分上具有很高的准确性,并且无论是对中国人还是美国人效果都相同。更为重要的是,这种miRNA诊断组合还能够正确预测I-II期肿瘤,并可以对美国队列中的NSCLC和良性结节病人进行区分。

总的来说,这项研究发现的5种血清miRNA能够准确诊断NSCLC,并且对不同种族的人群具有相同效果,这对于NSCLC的早期诊断手段开发具有重要意义。

原文出处:

Cheng Wanga, Meng DingaA. et al. Five-miRNA Panel Identified from a Multicentric Case-control Study Serves as a Novel Diagnostic Tool for Ethnically Diverse Non-small-cell Lung Cancer Patients.Ebiomedicine.2015

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (16)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1723626, encodeId=23141e23626e8, content=<a href='/topic/show?id=7b08915917b' target=_blank style='color:#2F92EE;'>#诊断工具#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91591, encryptionId=7b08915917b, topicName=诊断工具)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c37033510464, createdName=surilei, createdTime=Sun May 01 11:11:00 CST 2016, time=2016-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1915257, encodeId=edaf191525e67, content=<a href='/topic/show?id=e381586e94d' target=_blank style='color:#2F92EE;'>#新诊断#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58679, encryptionId=e381586e94d, topicName=新诊断)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8b48400, createdName=rgjl, createdTime=Tue Jan 12 20:11:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1858620, encodeId=b6f5185862048, content=<a href='/topic/show?id=e0a9593596' target=_blank style='color:#2F92EE;'>#DIC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5935, encryptionId=e0a9593596, topicName=DIC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f7770, createdName=jeanqiuqiu, createdTime=Sun May 22 16:11:00 CST 2016, time=2016-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=57750, encodeId=b19b5e7500f, content=嗯,, beContent=null, objectType=article, channel=null, level=null, likeNumber=139, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Sat Jan 16 00:31:00 CST 2016, time=2016-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=57751, encodeId=54805e7515e, content=嗯,, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Sat Jan 16 00:31:00 CST 2016, time=2016-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=57752, encodeId=0cb35e752ed, content=好消息!, beContent=null, objectType=article, channel=null, level=null, likeNumber=167, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Sat Jan 16 00:31:00 CST 2016, time=2016-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=57753, encodeId=e43c5e753c1, content=好消息!, beContent=null, objectType=article, channel=null, level=null, likeNumber=120, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Sat Jan 16 00:31:00 CST 2016, time=2016-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=57754, encodeId=a8f45e75413, content=不错~~, beContent=null, objectType=article, channel=null, level=null, likeNumber=157, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Sat Jan 16 00:31:00 CST 2016, time=2016-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=57755, encodeId=f0355e755b6, content=不错~~, beContent=null, objectType=article, channel=null, level=null, likeNumber=171, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Sat Jan 16 00:31:00 CST 2016, time=2016-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1997071, encodeId=fcde199e07157, content=<a href='/topic/show?id=9221645e6f' target=_blank style='color:#2F92EE;'>#EBI#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6457, encryptionId=9221645e6f, topicName=EBI)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1376173, createdName=linagood, createdTime=Mon Oct 26 22:11:00 CST 2015, time=2015-10-26, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1723626, encodeId=23141e23626e8, content=<a href='/topic/show?id=7b08915917b' target=_blank style='color:#2F92EE;'>#诊断工具#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91591, encryptionId=7b08915917b, topicName=诊断工具)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c37033510464, createdName=surilei, createdTime=Sun May 01 11:11:00 CST 2016, time=2016-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1915257, encodeId=edaf191525e67, content=<a href='/topic/show?id=e381586e94d' target=_blank style='color:#2F92EE;'>#新诊断#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58679, encryptionId=e381586e94d, topicName=新诊断)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8b48400, createdName=rgjl, createdTime=Tue Jan 12 20:11:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1858620, encodeId=b6f5185862048, content=<a href='/topic/show?id=e0a9593596' target=_blank style='color:#2F92EE;'>#DIC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5935, encryptionId=e0a9593596, topicName=DIC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f7770, createdName=jeanqiuqiu, createdTime=Sun May 22 16:11:00 CST 2016, time=2016-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=57750, encodeId=b19b5e7500f, content=嗯,, beContent=null, objectType=article, channel=null, level=null, likeNumber=139, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Sat Jan 16 00:31:00 CST 2016, time=2016-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=57751, encodeId=54805e7515e, content=嗯,, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Sat Jan 16 00:31:00 CST 2016, time=2016-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=57752, encodeId=0cb35e752ed, content=好消息!, beContent=null, objectType=article, channel=null, level=null, likeNumber=167, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Sat Jan 16 00:31:00 CST 2016, time=2016-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=57753, encodeId=e43c5e753c1, content=好消息!, beContent=null, objectType=article, channel=null, level=null, likeNumber=120, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Sat Jan 16 00:31:00 CST 2016, time=2016-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=57754, encodeId=a8f45e75413, content=不错~~, beContent=null, objectType=article, channel=null, level=null, likeNumber=157, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Sat Jan 16 00:31:00 CST 2016, time=2016-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=57755, encodeId=f0355e755b6, content=不错~~, beContent=null, objectType=article, channel=null, level=null, likeNumber=171, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Sat Jan 16 00:31:00 CST 2016, time=2016-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1997071, encodeId=fcde199e07157, content=<a href='/topic/show?id=9221645e6f' target=_blank style='color:#2F92EE;'>#EBI#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6457, encryptionId=9221645e6f, topicName=EBI)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1376173, createdName=linagood, createdTime=Mon Oct 26 22:11:00 CST 2015, time=2015-10-26, status=1, ipAttribution=)]
    2016-01-12 rgjl
  3. [GetPortalCommentsPageByObjectIdResponse(id=1723626, encodeId=23141e23626e8, content=<a href='/topic/show?id=7b08915917b' target=_blank style='color:#2F92EE;'>#诊断工具#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91591, encryptionId=7b08915917b, topicName=诊断工具)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c37033510464, createdName=surilei, createdTime=Sun May 01 11:11:00 CST 2016, time=2016-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1915257, encodeId=edaf191525e67, content=<a href='/topic/show?id=e381586e94d' target=_blank style='color:#2F92EE;'>#新诊断#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58679, encryptionId=e381586e94d, topicName=新诊断)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8b48400, createdName=rgjl, createdTime=Tue Jan 12 20:11:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1858620, encodeId=b6f5185862048, content=<a href='/topic/show?id=e0a9593596' target=_blank style='color:#2F92EE;'>#DIC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5935, encryptionId=e0a9593596, topicName=DIC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f7770, createdName=jeanqiuqiu, createdTime=Sun May 22 16:11:00 CST 2016, time=2016-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=57750, encodeId=b19b5e7500f, content=嗯,, beContent=null, objectType=article, channel=null, level=null, likeNumber=139, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Sat Jan 16 00:31:00 CST 2016, time=2016-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=57751, encodeId=54805e7515e, content=嗯,, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Sat Jan 16 00:31:00 CST 2016, time=2016-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=57752, encodeId=0cb35e752ed, content=好消息!, beContent=null, objectType=article, channel=null, level=null, likeNumber=167, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Sat Jan 16 00:31:00 CST 2016, time=2016-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=57753, encodeId=e43c5e753c1, content=好消息!, beContent=null, objectType=article, channel=null, level=null, likeNumber=120, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Sat Jan 16 00:31:00 CST 2016, time=2016-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=57754, encodeId=a8f45e75413, content=不错~~, beContent=null, objectType=article, channel=null, level=null, likeNumber=157, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Sat Jan 16 00:31:00 CST 2016, time=2016-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=57755, encodeId=f0355e755b6, content=不错~~, beContent=null, objectType=article, channel=null, level=null, likeNumber=171, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Sat Jan 16 00:31:00 CST 2016, time=2016-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1997071, encodeId=fcde199e07157, content=<a href='/topic/show?id=9221645e6f' target=_blank style='color:#2F92EE;'>#EBI#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6457, encryptionId=9221645e6f, topicName=EBI)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1376173, createdName=linagood, createdTime=Mon Oct 26 22:11:00 CST 2015, time=2015-10-26, status=1, ipAttribution=)]
    2016-05-22 jeanqiuqiu
  4. [GetPortalCommentsPageByObjectIdResponse(id=1723626, encodeId=23141e23626e8, content=<a href='/topic/show?id=7b08915917b' target=_blank style='color:#2F92EE;'>#诊断工具#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91591, encryptionId=7b08915917b, topicName=诊断工具)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c37033510464, createdName=surilei, createdTime=Sun May 01 11:11:00 CST 2016, time=2016-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1915257, encodeId=edaf191525e67, content=<a href='/topic/show?id=e381586e94d' target=_blank style='color:#2F92EE;'>#新诊断#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58679, encryptionId=e381586e94d, topicName=新诊断)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8b48400, createdName=rgjl, createdTime=Tue Jan 12 20:11:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1858620, encodeId=b6f5185862048, content=<a href='/topic/show?id=e0a9593596' target=_blank style='color:#2F92EE;'>#DIC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5935, encryptionId=e0a9593596, topicName=DIC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f7770, createdName=jeanqiuqiu, createdTime=Sun May 22 16:11:00 CST 2016, time=2016-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=57750, encodeId=b19b5e7500f, content=嗯,, beContent=null, objectType=article, channel=null, level=null, likeNumber=139, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Sat Jan 16 00:31:00 CST 2016, time=2016-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=57751, encodeId=54805e7515e, content=嗯,, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Sat Jan 16 00:31:00 CST 2016, time=2016-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=57752, encodeId=0cb35e752ed, content=好消息!, beContent=null, objectType=article, channel=null, level=null, likeNumber=167, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Sat Jan 16 00:31:00 CST 2016, time=2016-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=57753, encodeId=e43c5e753c1, content=好消息!, beContent=null, objectType=article, channel=null, level=null, likeNumber=120, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Sat Jan 16 00:31:00 CST 2016, time=2016-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=57754, encodeId=a8f45e75413, content=不错~~, beContent=null, objectType=article, channel=null, level=null, likeNumber=157, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Sat Jan 16 00:31:00 CST 2016, time=2016-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=57755, encodeId=f0355e755b6, content=不错~~, beContent=null, objectType=article, channel=null, level=null, likeNumber=171, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Sat Jan 16 00:31:00 CST 2016, time=2016-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1997071, encodeId=fcde199e07157, content=<a href='/topic/show?id=9221645e6f' target=_blank style='color:#2F92EE;'>#EBI#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6457, encryptionId=9221645e6f, topicName=EBI)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1376173, createdName=linagood, createdTime=Mon Oct 26 22:11:00 CST 2015, time=2015-10-26, status=1, ipAttribution=)]
    2016-01-16 medsic

    嗯,

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1723626, encodeId=23141e23626e8, content=<a href='/topic/show?id=7b08915917b' target=_blank style='color:#2F92EE;'>#诊断工具#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91591, encryptionId=7b08915917b, topicName=诊断工具)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c37033510464, createdName=surilei, createdTime=Sun May 01 11:11:00 CST 2016, time=2016-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1915257, encodeId=edaf191525e67, content=<a href='/topic/show?id=e381586e94d' target=_blank style='color:#2F92EE;'>#新诊断#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58679, encryptionId=e381586e94d, topicName=新诊断)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8b48400, createdName=rgjl, createdTime=Tue Jan 12 20:11:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1858620, encodeId=b6f5185862048, content=<a href='/topic/show?id=e0a9593596' target=_blank style='color:#2F92EE;'>#DIC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5935, encryptionId=e0a9593596, topicName=DIC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f7770, createdName=jeanqiuqiu, createdTime=Sun May 22 16:11:00 CST 2016, time=2016-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=57750, encodeId=b19b5e7500f, content=嗯,, beContent=null, objectType=article, channel=null, level=null, likeNumber=139, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Sat Jan 16 00:31:00 CST 2016, time=2016-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=57751, encodeId=54805e7515e, content=嗯,, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Sat Jan 16 00:31:00 CST 2016, time=2016-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=57752, encodeId=0cb35e752ed, content=好消息!, beContent=null, objectType=article, channel=null, level=null, likeNumber=167, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Sat Jan 16 00:31:00 CST 2016, time=2016-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=57753, encodeId=e43c5e753c1, content=好消息!, beContent=null, objectType=article, channel=null, level=null, likeNumber=120, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Sat Jan 16 00:31:00 CST 2016, time=2016-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=57754, encodeId=a8f45e75413, content=不错~~, beContent=null, objectType=article, channel=null, level=null, likeNumber=157, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Sat Jan 16 00:31:00 CST 2016, time=2016-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=57755, encodeId=f0355e755b6, content=不错~~, beContent=null, objectType=article, channel=null, level=null, likeNumber=171, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Sat Jan 16 00:31:00 CST 2016, time=2016-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1997071, encodeId=fcde199e07157, content=<a href='/topic/show?id=9221645e6f' target=_blank style='color:#2F92EE;'>#EBI#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6457, encryptionId=9221645e6f, topicName=EBI)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1376173, createdName=linagood, createdTime=Mon Oct 26 22:11:00 CST 2015, time=2015-10-26, status=1, ipAttribution=)]
    2016-01-16 medsic

    嗯,

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1723626, encodeId=23141e23626e8, content=<a href='/topic/show?id=7b08915917b' target=_blank style='color:#2F92EE;'>#诊断工具#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91591, encryptionId=7b08915917b, topicName=诊断工具)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c37033510464, createdName=surilei, createdTime=Sun May 01 11:11:00 CST 2016, time=2016-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1915257, encodeId=edaf191525e67, content=<a href='/topic/show?id=e381586e94d' target=_blank style='color:#2F92EE;'>#新诊断#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58679, encryptionId=e381586e94d, topicName=新诊断)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8b48400, createdName=rgjl, createdTime=Tue Jan 12 20:11:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1858620, encodeId=b6f5185862048, content=<a href='/topic/show?id=e0a9593596' target=_blank style='color:#2F92EE;'>#DIC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5935, encryptionId=e0a9593596, topicName=DIC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f7770, createdName=jeanqiuqiu, createdTime=Sun May 22 16:11:00 CST 2016, time=2016-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=57750, encodeId=b19b5e7500f, content=嗯,, beContent=null, objectType=article, channel=null, level=null, likeNumber=139, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Sat Jan 16 00:31:00 CST 2016, time=2016-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=57751, encodeId=54805e7515e, content=嗯,, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Sat Jan 16 00:31:00 CST 2016, time=2016-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=57752, encodeId=0cb35e752ed, content=好消息!, beContent=null, objectType=article, channel=null, level=null, likeNumber=167, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Sat Jan 16 00:31:00 CST 2016, time=2016-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=57753, encodeId=e43c5e753c1, content=好消息!, beContent=null, objectType=article, channel=null, level=null, likeNumber=120, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Sat Jan 16 00:31:00 CST 2016, time=2016-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=57754, encodeId=a8f45e75413, content=不错~~, beContent=null, objectType=article, channel=null, level=null, likeNumber=157, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Sat Jan 16 00:31:00 CST 2016, time=2016-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=57755, encodeId=f0355e755b6, content=不错~~, beContent=null, objectType=article, channel=null, level=null, likeNumber=171, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Sat Jan 16 00:31:00 CST 2016, time=2016-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1997071, encodeId=fcde199e07157, content=<a href='/topic/show?id=9221645e6f' target=_blank style='color:#2F92EE;'>#EBI#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6457, encryptionId=9221645e6f, topicName=EBI)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1376173, createdName=linagood, createdTime=Mon Oct 26 22:11:00 CST 2015, time=2015-10-26, status=1, ipAttribution=)]
    2016-01-16 medsic

    好消息!

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=1723626, encodeId=23141e23626e8, content=<a href='/topic/show?id=7b08915917b' target=_blank style='color:#2F92EE;'>#诊断工具#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91591, encryptionId=7b08915917b, topicName=诊断工具)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c37033510464, createdName=surilei, createdTime=Sun May 01 11:11:00 CST 2016, time=2016-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1915257, encodeId=edaf191525e67, content=<a href='/topic/show?id=e381586e94d' target=_blank style='color:#2F92EE;'>#新诊断#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58679, encryptionId=e381586e94d, topicName=新诊断)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8b48400, createdName=rgjl, createdTime=Tue Jan 12 20:11:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1858620, encodeId=b6f5185862048, content=<a href='/topic/show?id=e0a9593596' target=_blank style='color:#2F92EE;'>#DIC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5935, encryptionId=e0a9593596, topicName=DIC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f7770, createdName=jeanqiuqiu, createdTime=Sun May 22 16:11:00 CST 2016, time=2016-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=57750, encodeId=b19b5e7500f, content=嗯,, beContent=null, objectType=article, channel=null, level=null, likeNumber=139, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Sat Jan 16 00:31:00 CST 2016, time=2016-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=57751, encodeId=54805e7515e, content=嗯,, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Sat Jan 16 00:31:00 CST 2016, time=2016-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=57752, encodeId=0cb35e752ed, content=好消息!, beContent=null, objectType=article, channel=null, level=null, likeNumber=167, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Sat Jan 16 00:31:00 CST 2016, time=2016-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=57753, encodeId=e43c5e753c1, content=好消息!, beContent=null, objectType=article, channel=null, level=null, likeNumber=120, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Sat Jan 16 00:31:00 CST 2016, time=2016-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=57754, encodeId=a8f45e75413, content=不错~~, beContent=null, objectType=article, channel=null, level=null, likeNumber=157, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Sat Jan 16 00:31:00 CST 2016, time=2016-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=57755, encodeId=f0355e755b6, content=不错~~, beContent=null, objectType=article, channel=null, level=null, likeNumber=171, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Sat Jan 16 00:31:00 CST 2016, time=2016-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1997071, encodeId=fcde199e07157, content=<a href='/topic/show?id=9221645e6f' target=_blank style='color:#2F92EE;'>#EBI#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6457, encryptionId=9221645e6f, topicName=EBI)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1376173, createdName=linagood, createdTime=Mon Oct 26 22:11:00 CST 2015, time=2015-10-26, status=1, ipAttribution=)]
    2016-01-16 medsic

    好消息!

    0

  8. [GetPortalCommentsPageByObjectIdResponse(id=1723626, encodeId=23141e23626e8, content=<a href='/topic/show?id=7b08915917b' target=_blank style='color:#2F92EE;'>#诊断工具#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91591, encryptionId=7b08915917b, topicName=诊断工具)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c37033510464, createdName=surilei, createdTime=Sun May 01 11:11:00 CST 2016, time=2016-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1915257, encodeId=edaf191525e67, content=<a href='/topic/show?id=e381586e94d' target=_blank style='color:#2F92EE;'>#新诊断#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58679, encryptionId=e381586e94d, topicName=新诊断)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8b48400, createdName=rgjl, createdTime=Tue Jan 12 20:11:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1858620, encodeId=b6f5185862048, content=<a href='/topic/show?id=e0a9593596' target=_blank style='color:#2F92EE;'>#DIC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5935, encryptionId=e0a9593596, topicName=DIC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f7770, createdName=jeanqiuqiu, createdTime=Sun May 22 16:11:00 CST 2016, time=2016-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=57750, encodeId=b19b5e7500f, content=嗯,, beContent=null, objectType=article, channel=null, level=null, likeNumber=139, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Sat Jan 16 00:31:00 CST 2016, time=2016-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=57751, encodeId=54805e7515e, content=嗯,, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Sat Jan 16 00:31:00 CST 2016, time=2016-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=57752, encodeId=0cb35e752ed, content=好消息!, beContent=null, objectType=article, channel=null, level=null, likeNumber=167, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Sat Jan 16 00:31:00 CST 2016, time=2016-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=57753, encodeId=e43c5e753c1, content=好消息!, beContent=null, objectType=article, channel=null, level=null, likeNumber=120, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Sat Jan 16 00:31:00 CST 2016, time=2016-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=57754, encodeId=a8f45e75413, content=不错~~, beContent=null, objectType=article, channel=null, level=null, likeNumber=157, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Sat Jan 16 00:31:00 CST 2016, time=2016-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=57755, encodeId=f0355e755b6, content=不错~~, beContent=null, objectType=article, channel=null, level=null, likeNumber=171, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Sat Jan 16 00:31:00 CST 2016, time=2016-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1997071, encodeId=fcde199e07157, content=<a href='/topic/show?id=9221645e6f' target=_blank style='color:#2F92EE;'>#EBI#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6457, encryptionId=9221645e6f, topicName=EBI)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1376173, createdName=linagood, createdTime=Mon Oct 26 22:11:00 CST 2015, time=2015-10-26, status=1, ipAttribution=)]
    2016-01-16 medsic

    不错~~

    0

  9. [GetPortalCommentsPageByObjectIdResponse(id=1723626, encodeId=23141e23626e8, content=<a href='/topic/show?id=7b08915917b' target=_blank style='color:#2F92EE;'>#诊断工具#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91591, encryptionId=7b08915917b, topicName=诊断工具)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c37033510464, createdName=surilei, createdTime=Sun May 01 11:11:00 CST 2016, time=2016-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1915257, encodeId=edaf191525e67, content=<a href='/topic/show?id=e381586e94d' target=_blank style='color:#2F92EE;'>#新诊断#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58679, encryptionId=e381586e94d, topicName=新诊断)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8b48400, createdName=rgjl, createdTime=Tue Jan 12 20:11:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1858620, encodeId=b6f5185862048, content=<a href='/topic/show?id=e0a9593596' target=_blank style='color:#2F92EE;'>#DIC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5935, encryptionId=e0a9593596, topicName=DIC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f7770, createdName=jeanqiuqiu, createdTime=Sun May 22 16:11:00 CST 2016, time=2016-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=57750, encodeId=b19b5e7500f, content=嗯,, beContent=null, objectType=article, channel=null, level=null, likeNumber=139, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Sat Jan 16 00:31:00 CST 2016, time=2016-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=57751, encodeId=54805e7515e, content=嗯,, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Sat Jan 16 00:31:00 CST 2016, time=2016-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=57752, encodeId=0cb35e752ed, content=好消息!, beContent=null, objectType=article, channel=null, level=null, likeNumber=167, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Sat Jan 16 00:31:00 CST 2016, time=2016-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=57753, encodeId=e43c5e753c1, content=好消息!, beContent=null, objectType=article, channel=null, level=null, likeNumber=120, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Sat Jan 16 00:31:00 CST 2016, time=2016-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=57754, encodeId=a8f45e75413, content=不错~~, beContent=null, objectType=article, channel=null, level=null, likeNumber=157, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Sat Jan 16 00:31:00 CST 2016, time=2016-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=57755, encodeId=f0355e755b6, content=不错~~, beContent=null, objectType=article, channel=null, level=null, likeNumber=171, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Sat Jan 16 00:31:00 CST 2016, time=2016-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1997071, encodeId=fcde199e07157, content=<a href='/topic/show?id=9221645e6f' target=_blank style='color:#2F92EE;'>#EBI#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6457, encryptionId=9221645e6f, topicName=EBI)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1376173, createdName=linagood, createdTime=Mon Oct 26 22:11:00 CST 2015, time=2015-10-26, status=1, ipAttribution=)]
    2016-01-16 medsic

    不错~~

    0

  10. [GetPortalCommentsPageByObjectIdResponse(id=1723626, encodeId=23141e23626e8, content=<a href='/topic/show?id=7b08915917b' target=_blank style='color:#2F92EE;'>#诊断工具#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91591, encryptionId=7b08915917b, topicName=诊断工具)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c37033510464, createdName=surilei, createdTime=Sun May 01 11:11:00 CST 2016, time=2016-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1915257, encodeId=edaf191525e67, content=<a href='/topic/show?id=e381586e94d' target=_blank style='color:#2F92EE;'>#新诊断#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58679, encryptionId=e381586e94d, topicName=新诊断)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8b48400, createdName=rgjl, createdTime=Tue Jan 12 20:11:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1858620, encodeId=b6f5185862048, content=<a href='/topic/show?id=e0a9593596' target=_blank style='color:#2F92EE;'>#DIC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5935, encryptionId=e0a9593596, topicName=DIC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f7770, createdName=jeanqiuqiu, createdTime=Sun May 22 16:11:00 CST 2016, time=2016-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=57750, encodeId=b19b5e7500f, content=嗯,, beContent=null, objectType=article, channel=null, level=null, likeNumber=139, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Sat Jan 16 00:31:00 CST 2016, time=2016-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=57751, encodeId=54805e7515e, content=嗯,, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Sat Jan 16 00:31:00 CST 2016, time=2016-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=57752, encodeId=0cb35e752ed, content=好消息!, beContent=null, objectType=article, channel=null, level=null, likeNumber=167, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Sat Jan 16 00:31:00 CST 2016, time=2016-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=57753, encodeId=e43c5e753c1, content=好消息!, beContent=null, objectType=article, channel=null, level=null, likeNumber=120, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Sat Jan 16 00:31:00 CST 2016, time=2016-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=57754, encodeId=a8f45e75413, content=不错~~, beContent=null, objectType=article, channel=null, level=null, likeNumber=157, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Sat Jan 16 00:31:00 CST 2016, time=2016-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=57755, encodeId=f0355e755b6, content=不错~~, beContent=null, objectType=article, channel=null, level=null, likeNumber=171, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Sat Jan 16 00:31:00 CST 2016, time=2016-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1997071, encodeId=fcde199e07157, content=<a href='/topic/show?id=9221645e6f' target=_blank style='color:#2F92EE;'>#EBI#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6457, encryptionId=9221645e6f, topicName=EBI)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1376173, createdName=linagood, createdTime=Mon Oct 26 22:11:00 CST 2015, time=2015-10-26, status=1, ipAttribution=)]
    2015-10-26 linagood

相关资讯

Lancet:诱导化疗治疗IIIA/N2期非小细胞肺癌

IIIA/N2期非小细胞肺癌的治疗标准选择之一是新辅助化疗和手术。研究人员做了一项随机试验,探讨增加新辅助放疗能否可以改善预后。研究人员在瑞士,德国和塞尔维亚的23个中心招募患者参加研究。符合条件的患者已经病理证实为IIIA/N2期非小细胞肺癌患者,被随机以1:1的比例分配到治疗组中。那些化疗组中的患者接受三个周期的新辅助化疗(100mg/m2的铂和85mg/m2的多西他赛),随后进行3周44Gy

N Engl J Med.:AZD9291对 EGFR抑制剂抵抗的非小细胞肺癌有效

背景:肺癌表皮生长因子受体突变(EGFR-突变肺癌)患者EGFR T790M突变是表皮生长因子受体(EGFR)酪氨酸激酶抑制剂最常见的耐药机制。在临床前模型中,EGFR抑制剂AZD9291已证明对表皮生长因子受体酪氨酸激酶抑制剂-敏化和T790M抵抗突变是有效的。方法:先前EGFR酪氨酸激酶抑制剂治疗后放射记录疾病仍有进展的晚期肺癌患者,以AZD9291  20到24

FDA批准阿斯利康易瑞沙治疗晚期EGFR突变阳性肺癌

阿斯利康(AstraZeneca)肿瘤学管线在监管方面收获喜讯,FDA近日批准靶向治疗药物易瑞沙(Iressa,通用名:gefitinib,吉非替尼)作为一种单药疗法,用于经一款FDA批准的伴随诊断试剂盒证实为表皮生长因子受体(EGFR)突变阳性的转移性非小细胞肺癌(NSCLC)患者的一线治疗,具体为EGFR存在外显子19删除突变或外显子21存在L858R替代突变。据估计,10-15%的白种人NS

贝伐珠单抗获CFDA批准用于联合化疗非小细胞肺癌

7月7日,罗氏宣布其抗肿瘤药物安维汀®(通用名:贝伐珠单抗)已通过中国国家食品药品监督管理局的批准,将用于晚期转移性非鳞非小细胞肺癌一线治疗 。安维汀®的获批上市,不仅为中国肺癌患者提供了全新的治疗选择,同时,也将开辟中国肺癌抗血管生成治疗的全新格局。作为全球首款抗肿瘤血管生成治疗药物,安维汀®在120多个国家地区获批用于多个实体肿瘤的治疗,为数以百万计的患者带来获益。 同时,罗氏将支持中华

CLIN CANCER RES :Anti-NaPi2b抗体药物偶联物作为非小细胞肺癌和卵巢癌治疗的临床前景

目的:抗体药物偶联物(ADCs)有选择性的输送细胞毒性药物到细胞,表达易进入的靶目抗原。这里我们偶联单甲基阿里他汀 E(MMAE)到抗体识别SLC34A2基因产物NaPi2b,II型磷酸钠协同转运蛋白,其在肺部、卵巢、甲状腺肿瘤表面高度表达,也在正常的肺细胞中有表达。本研究评估临床前研究的有效性和安全性。实验设计:抗NaPi2b 抗体药物偶联物ADC的疗效通过卵巢癌小鼠和非小细胞肺癌(NSCLC)

Ann Oncol:引发非小细胞肺癌患者死亡的并发症

许多非小细胞肺癌(NSCLC)患者在确诊后的前几年就会死亡,在确诊5年后仍有相当大的死亡数。本研究调查了在长期随访期间不同年龄和疾病阶段的非小细胞患者死亡率和死因的分布。 研究人员收纳了来自荷兰癌症登记处在1989-2008年间确诊为I–III期非小细胞肺癌并于2011年前死亡的72021名患者,年龄在45-89岁。在确诊为非小细胞肺癌后的5个时间段内,计算了死亡比率及死亡原因分布比例。 平均

Baidu
map
Baidu
map
Baidu
map